Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis

Company Overview

Lakefront is a clinical-stage biotechnology company developing therapies in immunology and inflammation. Its clinical-stage portfolio includes lead asset gamgertamig, a BCMAxCD3 T-cell engager being developed for the treatment of autoimmune diseases.

The company identifies, acquires, and advances therapeutic assets through business development and clinical development activities. Lakefront evaluates opportunities for portfolio expansion based on their scientific, clinical, and commercial potential.

Lakefront focuses on developing medicines for diseases with unmet medical needs and advancing its product candidates through clinical development.

Key Stats

• Today's Range: $29.33 to $29.95
• 50-Day Range: $26.08 to $30.72
• 52-Week Range: $25.68 to $36.24
• Volume: 212,541 shs
• Average Volume: 383,777 shs
• Market Capitalization: $1.96 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.00
• Consensus Rating: Moderate Buy

Lakefront Biotherapeutics American Depositary Shares Stock Analysis - MarketRank™

Lakefront Biotherapeutics American Depositary Shares scored higher than 63% of companies evaluated by MarketBeat, and ranked 298th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Lakefront Biotherapeutics American Depositary Shares has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.

Upside Potential

Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $37.00, representing about 24.5% upside from its current price of $29.73.

Amount of Analyst Coverage

Lakefront Biotherapeutics American Depositary Shares has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Lakefront Biotherapeutics American Depositary Shares are expected to decrease in the coming year, from ($1.27) to ($1.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -21.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -21.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lakefront Biotherapeutics American Depositary Shares has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.19% of the float of Lakefront Biotherapeutics American Depositary Shares has been sold short.

Short Interest Ratio / Days to Cover

Lakefront Biotherapeutics American Depositary Shares has a short interest ratio ("days to cover") of 9.48.

Change versus previous month

Short interest in Lakefront Biotherapeutics American Depositary Shares has recently decreased by 2.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lakefront Biotherapeutics American Depositary Shares does not currently pay a dividend.

Dividend Growth

Lakefront Biotherapeutics American Depositary Shares does not have a long track record of dividend growth.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.06

News Sentiment

Lakefront Biotherapeutics American Depositary Shares has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Lakefront Biotherapeutics American Depositary Shares this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Lakefront Biotherapeutics American Depositary Shares to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lakefront Biotherapeutics American Depositary Shares insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.91% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by insiders.

Percentage Held by Institutions

32.46% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LKFT
• Previous Symbol: NASDAQ:GLPG
• CIK: 1421876
• Web: www.glpg.com
• Phone: (321) 534-2900
• Fax: 321-534-2901
• Employees: 1,310
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Lakefront Biotherapeutics American Depositary Shares: $37.00
• High Price Target: $45.00
• Low Price Target: $26.00
• Potential Upside/Downside: +24.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.84
• Quick Ratio: 32.72

Sales & Book Value

• Annual Sales: $1.26 billion
• Price / Sales: 1.56
• Cash Flow: $0.73 per share
• Price / Cash Flow: 40.64
• Book Value: $47.57 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 65,900,000
• Free Float: 63,979,000
• Market Cap: $1.96 billion
• Optionable: Optionable
• Beta: 0.24